LOVENOX
What it isLow-molecular-weight heparin that activates antithrombin to inhibit factor Xa; VTE and acute coronary syndromes.
Why this oneIt is the US default LMWH, with unusually broad use across VTE, pregnancy, and acute coronary syndromes.
What limits itRenal impairment increases bleeding risk. Protamine reverses it only partly; neuraxial procedures risk spinal hematoma.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| VTE prophylaxis, abdominal surgery | adult | 40 mg SC QD (first dose 2 h pre-op) | 40 mg SC QD | 40 mg SC QD |
| VTE prophylaxis, hip/knee replacement | adult | 30 mg SC q12h (start 12-24 h post-op) | 30 mg SC q12h; hip: 40 mg SC QD up to 3 wk | — |
| VTE prophylaxis, acute medical illness | adult | 40 mg SC QD | 40 mg SC QD | 40 mg SC QD |
| DVT treatment, outpatient (no PE) | adult | 1 mg/kg SC q12h | 1 mg/kg SC q12h | — |
| DVT treatment, inpatient (with/without PE) | adult | 1 mg/kg SC q12h or 1.5 mg/kg SC QD | 1 mg/kg SC q12h or 1.5 mg/kg SC QD | — |
| Unstable angina / NSTEMI | adult | 1 mg/kg SC q12h + aspirin | 1 mg/kg SC q12h | — |
| Acute STEMI | <75 yr | 30 mg IV bolus + 1 mg/kg SC, then 1 mg/kg SC q12h | 1 mg/kg SC q12h | 100 mg for first two doses only |
| Acute STEMI | >=75 yr | reduced dose, no IV bolus (see 2.4) | reduced dose q12h | — |
Renal CrCl <30 mL/min: reduce dose (prophylaxis 30 mg SC QD; treatment 1 mg/kg SC QD).
Hepatic Undefined
STEMI: max 100 mg for the first two doses only; reduce dose in patients >=75 yr.
Pregnancy Human cohort data (693 live births) suggest no increased risk of major malformations.
Lactation Undefined
⚠ BOXED WARNING
Cost, est. cash$4–$300/month
Generic entry2010
Legacy pregnancy categoryB
Defining liabilityMajor bleeding, accumulation in renal impairment and heparin-induced thrombocytopenia.

Open Enoxaparin in the interactive console ↗

